Taysha Gene Therapies (TSHA) Gains from Investment Securities (2019 - 2026)

Taysha Gene Therapies has disclosed Gains from Investment Securities across 8 years of filings, most recently posting $4.5 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $4.5 million, up 63872.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (up 106.79% YoY), and the FY2025 annual result was $24.6 million, up 563.83% from the prior year.
• Gains from Investment Securities came in at $4.5 million for Q1 2026 at Taysha Gene Therapies, up from -$759000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $9.5 million in Q3 2025 to a low of -$66.0 million in Q4 2023.
• The 5-year median for Gains from Investment Securities is $1.9 million (2022), against an average of -$1.7 million.
• Across the five-year window, Gains from Investment Securities tumbled 22643.45% in 2023 and surged 63872.7% in 2026, its largest moves.
• Taysha Gene Therapies' Gains from Investment Securities stood at -$290000.0 in 2022, then sank by 22643.45% to -$66.0 million in 2023, then soared by 99.87% to -$83000.0 in 2024, then tumbled by 814.46% to -$759000.0 in 2025, then soared by 688.15% to $4.5 million in 2026.
• The last three Gains from Investment Securities figures came in at $4.5 million (Q1 2026), -$759000.0 (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.